Pharma stocks in focus after medicine tariff changes in Union Budget 2025

Shares of Pharma stocks like Lupin, and Cipla will remain in focus after Finance Minister Nirmala Sitharaman on Saturday, in her Budget announcement, stated critical changes in tariffs for certain medicines.

Sitharaman stated that the government has taken steps to improve access to critical medicines by adding six life-saving drugs to the concessional 5% duty slab. Furthermore, full exemption and concessional duty will now apply to certain bulk drugs.

Additionally, in a move to reduce costs for patients, customs duties will be eliminated on 36 additional life-saving drugs.


These medicines also include the medication given to cancer patients, thereby reducing the monetary burden on them and making these drugs more affordable for them.

This update is likely to affect drug manufacturers like Aarti Drugs, Cipla, Abbott India, Ajanta Pharma, Akum Drugs & Pharmaceuticals, Alkem Laboratories, Astrazeneca Pharma, Biocon, Lupin and Dr. Lal Path Laboratories among others.

Also read: Budget 2025 Live Updates: Bihar shines brighter in Nirmala Sitharaman's Budget 2025 - Gareeb, youth, annadata and naari also feature in FM's speech

“Our economy is the fastest-growing among all major global economies. Our development track record of the past 10 years and structural reforms have drawn global attention. Confidence in India’s capability and potential has only grown in this period. We see the next five years as a unique opportunity to realize ‘Sabka Vikas’,” quoted the finance minister while presenting the Union Budget 2025.

The Union Budget 2025 was the second full budget of Modi 3.0 and there were expectations of increased focus on agriculture while balancing between fiscal consolidation and economic growth.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)